Your Location：
Home >
Browse articles >
Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
LETTER TO THE EDITOR | Updated：2023-03-20
Previous|Next

    • Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

    • Jiang-Yi Wang , Guo-Peng Yu , Long Li , Guo-Wen Lin , Ding-Wei Ye
    • Military Medical Research Vol. 9, Issue 6, Pages: 754-756(2022)

    • DOI： 10.1186/s40779-021-00364-x     

      CLC：

    Scan QR Code

  •  
  •  

  • Full Text(HTML)

  • References

  • Publication Info

  • Metrics

Sections
icon
The trial reading is over, you can activate your VIP account to continue reading.
Deactivate >
icon
The trial reading is over. You can log in to your account, go to the personal center, purchase VIP membership, and read the full text.
Already a VIP member?
Log in >

33

Views

23

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Standardizing the classification of gastric cancer patients with limited and adequate number of retrieved lymph nodes: an externally validated approach using real-world data
Immune microenvironment dynamics in pregnant patients with concomitant autoimmune diseases: mechanisms, challenges, and clinical significance
Metabolic syndrome and risk of sepsis and sepsis-related mortality: evidence from two large prospective cohort studies
Frostbite: diagnosis, treatment, prognosis, and future directions
Engineering of functional auditory neurons from human induced pluripotent stem cells

Related Author

Wei Wang
Yu-Jie Yang
Ri-Hong Zhang
Jing-Yu Deng
Zhe Sun
Sharvesh Raj Seeruttun
Zhen-Ning Wang
Hui-Mian Xu

Related Institution

Department of Gastric Surgery, Sun Yat-sen University Cancer Center
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital
Department of Surgical Oncology, the First Hospital of China Medical University